TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06732882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: Participants will receive AZD4604 via Genuair/Turbuhaler device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: Participants will receive AZD4604 via Genuair/Turbuhaler device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: Participants will receive AZD4604 via Genuair/Turbuhaler device.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo via Genuair/Turbuhaler device.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo via Genuair/Turbuhaler device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genuair
Description: Participants will either receive AZD4604 or placebo via Genuair device.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Genuair
Description: Participants will either receive AZD4604 or placebo via Genuair device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Description: Participants will receive either AZD4604 or placebo via Turbuhaler device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Description: Participants will receive either AZD4604 or placebo via Turbuhaler device.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Turbuhaler
Description: Participants will receive either AZD4604 or placebo via Turbuhaler device.
Study: NCT06732596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embodied conversational agent (ECA)
Description: The app with the ECA will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embodied conversational agent (ECA)
Description: The app with the ECA will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embodied conversational agent (ECA)
Description: The app with the ECA will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technical support
Description: Technical support will include assistance downloading and setting up the app on the participant's phone, walking them through a brief demonstration, and answering any questions the participant has about how to use the app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technical support
Description: Technical support will include assistance downloading and setting up the app on the participant's phone, walking them through a brief demonstration, and answering any questions the participant has about how to use the app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technical support
Description: Technical support will include assistance downloading and setting up the app on the participant's phone, walking them through a brief demonstration, and answering any questions the participant has about how to use the app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional ECA messages
Description: Weekly text messages will be provided reminding participants to use the app on behalf of OBAT clinical staff.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional ECA messages
Description: Weekly text messages will be provided reminding participants to use the app on behalf of OBAT clinical staff.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional incentives
Description: Additional incentives will be provided after logging into the app for 20 days followed by monthly lotteries for those who log in 15 days per month
Study: NCT06734026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cafe Therapy
Description: Participants will be volunteer workers for two hours per day, three days per week for 6-8 weeks, alongside a trained researcher. Participants will complete at least 18 sessions of training within the time frame. Participants will run the Café with supervision from a researcher, serving customers prepackaged food and drinks per our protocol, along with guidance and direction from a therapist, once a week. Participants will be responsible for interacting with customers and arranging supplies. On a weekly basis, participants will be asked how they feel (for example tired, stressed, overwhelmed, etc) before and after their session and to rate how well they performed in the café.
Study: NCT06732206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Solution Focused Approach Program
Description: It will be a psychoeducational approach aimed at developing preventive and protective properties against addiction.
Study: NCT06732869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth physical activity coaching intervention
Description: Patients will attend a PR program and in week 5 of PR will receive an eHealth PA coaching intervention until 6 months after end of PR. The PA goals will be prescribed through a phone call and the personalisation of goal prescription will be based on an algorithm considering patient's performance in the previous week, perceived easiness of achieving the previous goal and confidence to change it. If patient does not achieve the goal, reasons, barriers to PA and strategies to overcome them will be identified. Patients will receive a daily notification about their goal achievements, at 6PM every day, giving them the possibility to increase their PA to achieve the goal, if they have not reached it yet. Patients will also receive personalized notifications sent manually by the researcher whenever appropriate. PA goals will be prescribed on a weekly basis.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: pulmonary rehabilitation
Description: Patients will attend pulmonary rehabilitation program for 10 weeks. Pulmonary rehabilitation is evidence-based multidisciplinary intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to exercise training, education, self-management intervention aiming at behaviour change, known to improve health status and psychological well-being, reducing dyspnoea and healthcare utilization and hospitalization. In this study, pulmonary rehabilitation programs will have 20 sessions, twice a week, including exercise training (aerobic and strength training), educational sessions about topics as medication, smoking cessation, energy conservation techniques, physical activity, stress and anxiety management, breathing control, inhaled therapy and nutrition; nutritional and psychosocial counselling. Education session about PA importance and recommendations will be also provided in both arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Patients will attend pulmonary rehabilitation program for 10 weeks. Pulmonary rehabilitation is evidence-based multidisciplinary intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to exercise training, education, self-management intervention aiming at behaviour change, known to improve health status and psychological well-being, reducing dyspnoea and healthcare utilization and hospitalization. In this study, pulmonary rehabilitation programs will have 20 sessions, twice a week, including exercise training (aerobic and strength training), educational sessions about topics as medication, smoking cessation, energy conservation techniques, physical activity, stress and anxiety management, breathing control, inhaled therapy and nutrition; nutritional and psychosocial counselling. Education session about PA importance and recommendations will be also provided in both arms.
Study: NCT06733116

Intervention type: OTHER
Intervention: Delphi method survey
Description: This intervention involves a Delphi method study, where a panel of experts in isokinetic testing will collaborate to reach a consensus on best practices for standardizing the reporting of isokinetic test data. Unlike other clinical studies, this intervention focuses on gathering expert opinions iteratively to establish a unified framework for data reporting, without direct clinical or experimental treatment. The process includes multiple rounds of feedback, refining key elements related to testing protocols, measurement parameters, and result presentation, ensuring broad expertise from various fields such as medicine, rehabilitation, and biomechanics.
Study: NCT06733207

Intervention type: OTHER
Intervention: Pupil examination
Description: Pupil assessment : bilateral clinical examination of the patient's pupils, assessed in qualitative data : mydriasis, myosis, pupillary light reflex, anisocoria or isochoria.
Study: NCT06724601

Intervention type: DEVICE
Intervention: Electrical Impedance Tomography
Description: Electrical Impedance Tomography data and the physiological and clinical parameters will be recorded continuously in three different positions (supine 1, car seat, supine 2) to assess alterations in lung volume and cardiorespiratory events.
Study: NCT05715996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mixed reality guided localization
Description: In this study, MR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
Study: NCT05965011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The intervention will be a combination of both supervised and unsupervised sessions. Participants in the Nordic Walking (NW) treatment group will attend 5 one-hour group sessions, which will incorporate coaching principles.
Study: NCT02327754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiroxostat BID, (Oral daily dosing for 28 weeks)
Description: The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID, (Oral daily dosing for 28 weeks)
Description: Subjects randomized to the placebo arm will receive placebo.
Study: NCT02026089

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella vaccine
Description: Varivax 0.5ml subcutaneous injection
Study: NCT05308732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copaiba
Description: A 10% and 15% aqueous solution of copaiba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula: 10% copaiba oil (Copaifera Officinalis Resin) and 15% liquid mint aroma 5% , tween 80 1%, Aqueous solution (Distilled water + 0.1% Nipagin) qsp 100%.
Study: NCT05422417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolonged intermittent theta burst stimulation (piTBS)
Description: Participants in the prolonged dosage (1800 pulse) of intermittent TBS (iTBS) active stimulation group will receive 2-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20Hz rTMS
Description: Participants in the 20 Hz rTMS (2000 pulse) active stimulation group will receive 2-week 2s- and-10s off, total 50 cycles at each hemisphere/session, at an intensity of 100% resting motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham control
Description: Half of the patients in the sham group received 2-week the same prolonged iTBS parameter stimulation (sham- prolonged iTBS), and the other half received the same 20 Hz rTMS parameter stimulation using a sham coil (sham-20 Hz rTMS), which also improved the blinding process
Study: NCT06495671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetically enhanced diffusion
Description: Iron nanoparticle (intra-arterial) + External magnet workstation
Study: NCT04979559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile health apps
Description: Mobile health application intervention including screening and early intervention such as diet and physical activity suggestion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Regular practice for screening and early intervention for prediabetes patient in primary health cares setting
Study: NCT05741580

Intervention type: PROCEDURE
Intervention: Evolution of symptoms
Description: percentage of patients with improvement in their symptoms
Study: NCT06174766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP2102-1
Description: Test drug
Study: NCT00998179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acu-TENS
Description: Application of Acu-TENS (with electrical output from the machine)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-TENS
Description: Application of Acu-TENS (without electrical output from the machine)
Study: NCT05411471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
Description: The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
Description: The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
Description: The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
Study: NCT06020222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Both hands and feet received cryotherapy gloves and boots, and the frequency was once every three weeks. Each cycle was 90 minutes, and the cycle was performed 4 times.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: education
Description: Provide preventive CIPN education leaflets
Study: NCT04867837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octaplex
Description: Four-factor prothrombin complex concentrate (4F-PCC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octaplex
Description: Four-factor prothrombin complex concentrate (4F-PCC)
Study: NCT05411471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
Description: The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
Study: NCT04851444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-F019
Description: Single dose is administered IV.
Study: NCT05829655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant (20mg/day)
Description: Double blind administration of suvorexant once per day during residential stay until discharge.
Study: NCT04466917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 215
Description: ABP 215 will be administered at a dose of 15 mg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered 175 mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered 175 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
Study: NCT06174766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP2102-1
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP2102-2
Description: Test drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2209-1
Description: Control drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2209-2
Description: Control drug
Study: NCT06577792

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lobectomy-First
Description: During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lobectomy first, and then perform lymphadenectomy next.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lymphadenectomy-First
Description: During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lymphadenectomy first, and then perform lobectomy next.
Study: NCT05829655

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind administration of placebo once per day during residential stay until discharge.
Study: NCT06575816

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Reality Video Intervention
Description: This intervention involves a video intervention using augmented reality (AR) technology to reduce the pain, anxiety and fear children experience during the blood collection process. During the intervention, children watch AR videos to distract and relax them from the blood collection process. These videos are equipped with a variety of entertaining and engaging content and aim to reduce children's psychological stress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Video Intervention
Description: This intervention involves a video intervention using augmented reality (AR) technology to reduce the pain, anxiety and fear children experience during the blood collection process. During the intervention, children watch AR videos to distract and relax them from the blood collection process. These videos are equipped with a variety of entertaining and engaging content and aim to reduce children's psychological stress.
Study: NCT06572306

Intervention type: DEVICE
Intervention: FreeStyle Libre 2 Continuous Glucose Monitor
Description: Subjects included in the intervention group (continuous glucose monitoring) will be recruited from the USF Health Department of Family Medicine. Each subject will be enrolled for 12 weeks.
Study: NCT06575114

Intervention type: OTHER
Group type: OTHER
Intervention: Self-determination theory-based health education measures
Description: In the control group, a conventional intervention will be used, and health education brochures on the COVID-19 vaccine will be distributed for the study participants to read on their own time. The intervention group will receive self-determination theory-based interventions, with targete interventions proposed based on the self-determination theory-including health-related talks and sharing sessions. To ensure that older individuals with varying levels of literacy understood the intervention, the process will be conducted in the local native dialect.

Intervention type: OTHER
Group type: OTHER
Intervention: Self-determination theory-based health education measures
Description: In the control group, a conventional intervention will be used, and health education brochures on the COVID-19 vaccine will be distributed for the study participants to read on their own time. The intervention group will receive self-determination theory-based interventions, with targete interventions proposed based on the self-determination theory-including health-related talks and sharing sessions. To ensure that older individuals with varying levels of literacy understood the intervention, the process will be conducted in the local native dialect.
Study: NCT06576414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: the first hour of ACT intervention followed by 1 hour of back exercise class, which led by a trained ACT counsellor and a trained exercise trainer
Study: NCT06086327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Pentixafor
Description: Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
Study: NCT06135103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talfirastide
Description: TXA127, a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II) is a sterile solution containing angiotensin (1-7) \[A(1-7)\], supplied in a 3 mL, single-use, stoppered vial.
Study: NCT06576414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: back exercise
Description: 1 hour of back exercise class led by a trained exercise trainer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: back exercise
Description: 1 hour of back exercise class led by a trained exercise trainer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: back care education
Description: 1 hour long interactive lesson to participants about LBP-related pathology, disability, psychology, and pain management skills.
Study: NCT06135103

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile solution containing supplied in a 3 mL, single-use, stoppered vial.
Study: NCT05707026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cross fiber fascial manipulation
Description: The group A received three sessions of fascial manipulation in two weeks. FM applied for 5 to 8 minutes at each point.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching techniques(sleeper stretch and cross body adduction stretch)
Description: Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets.
Study: NCT05243433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery using the Maestro Platform
Description: Laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic bariatric surgery (gastric sleeve or gastric bypass), or laparoscopic colectomy performed using the Maestro Platform.